Avidity Biosciences, INC 10-Q quarterly reports

Atrium Therapeutics, Inc. (Atrium) reported its financial results for the second quarter ended June 30, 2026, highlighting progress in its RNA delivery platform and advancing its lead product candidates for cardiomyopathies.

Avidity Biosciences announces its acquisition by Novartis AG for $72.00 per share in cash, alongside a spin-off of its early-stage cardiology programs.

Avidity Biosciences, Inc. reported a significant increase in net loss for the first half of 2025, driven by higher R&D and G&A expenses, while advancing three key RNA therapeutic programs into late-stage clinical trials.

Avidity Biosciences reports a net loss of $115.8 million for Q1 2025 and provides updates on its clinical programs and pipeline advancements.

Avidity Biosciences reports a strong cash position of $1.6 billion and advancements in its clinical programs for myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy in its Q3 2024 filing.

Avidity Biosciences reports a net loss of $139.6 million for the first six months of 2024, alongside significant cash and marketable securities growth to $1.3 billion.

Avidity Biosciences reported a net loss of $68.9 million for the first quarter of 2024, while highlighting progress in clinical development and a strong cash position.